Serina Therapeutics, Inc.

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates.

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina's common stock to three new non-executive employees on November 6, 2024 (each, an “Option Grant”). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on November 6, 2024. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were approved by the Compensation Committee of Serina's Board of Directors on November 6, 2024 pursuant to Serina's 2024 Inducement Equity Plan to align their interests with Serina's stockholders and to promote the success of Serina's business. The Option Grants were made in reliance on the employment inducement exemption under the NYSE American's Company Guide Section 711(a) which requires public disclosure of inducement awards. Serina is issuing this press release pursuant to Section 711(a) of NYSE American's Company Guide. The Option Grants shall vest and become exercisable with respect to one-third of the aggregate number of shares subject to each Option Grant on the first anniversary of the grant date, and the remaining two-thirds of the aggregate number of shares subject to each Option Grant shall vest in a series of 24 substantially equal monthly installments thereafter, such that the Option Grant will be vested as of the third anniversary of the grant date, subject to continued employment with Serina.

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced that Steve Ledger, Interim Chief Executive Officer of Serina, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 12:00 p.m. ET.

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics  (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights.

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th Annual mRNA-Based Therapeutics Summit. The conference will take place from July 29-31, 2024, in Boston, MA.

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Formulation. Dr. Tenjarla brings over 20 years of extensive experience in drug development to Serina.

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights.

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM drug delivery technology today announced the appointment of Dr. Simba Gill as Executive Chairman. Serina's proprietary POZ PlatformTM aims to develop and improve therapeutics across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

AgeX Therapeutics Inc

HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases, today announced the closing of its previously announced merger with a wholly-owned subsidiary of AgeX Therapeutics, Inc. The combined company will operate under the name Serina Therapeutics and will trade on the NYSE American market under the ticker symbol “SER” effective with the open of business on Wednesday, March 27, 2024. The new CUSIP number for the combined company following the merger is 81751A108.

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

News for Serina Therapeutics, Inc. Stock (SER)